- Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseasesLast month, Ascidian Therapeutics presented the first data suggesting a new way to fix broken genes may be safe in people. Now Eli Lilly has struck a deal with the startup. Ascidian’s ...Endpoints · 1mo ago↗ source
- Lilly gives hospitals deadline to comply with 340B claims data policyEli Lilly is giving a group of hospitals five days to comply with its new claims data policy or risk losing their 340B discounts. Some health centers aren’t cooperating with Lilly's recent push t…Endpoints · 1mo ago↗ source
- FDA details flexibilities for new cell and gene therapies to leverage past dataThe FDA is further explaining to cell and gene therapy developers the types of prior knowledge companies can leverage for clinical, nonclinical and manufacturing-related work, according to new CBER…